Key facts
- This page summarizes Emster Kurt von's Form 4 filing for Vera Therapeutics, Inc. (VERA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2021, 20:34.
Emster Kurt von - 13 May 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- VERA
- Reported as of
- 13 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 May 2021, 20:34:38 UTC
- Next SEC filing
- 18 May 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Joseph R. Young, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Emster Kurt von filed Form 4 for Vera Therapeutics, Inc. (VERA) on 17 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VERA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +9,925
- Change %
- Price
- $0.000000
- Shares after
- 9,925
- Date
- 13 May 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 9,925
- Exercise price
- $11.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders.